(PharmaNewsWire.Com, May 20, 2025 ) InsightAce Analytics Pvt. Ltd. announces the release of a market assessment report on the “Global Minimal Residual Disease Market (By Product (Assay Kits & Reagents, Instruments), By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Flow Cytometry, Other Technologies), By Application (Hematological Malignancies, Lymphoma, Solid Tumors, Multiple Myeloma, Other Applications), By End User (Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes, Other End Users)- Market Outlook And Industry Analysis 2034″
The global minimal residual disease market is estimated to reach over USD 4.6 Bn by the year 2034, exhibiting a CAGR of 12.8 % during the forecast period.
Global Minimal Residual Disease Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1448
The minimal residual illnesses are leukemic cells that remain in a patient during or after treatment. Cancer treatment, such as chemotherapy or radiotherapy, is not always effective in eradicating all carcinogenic cells and may also cause cancer. Organ transplants requiring a major histocompatibility test may be one of the instances where minimal residual disease testing is used for greater specificity.
The highly financed oncology testing market is predicted to increase the number of technologies and the specificity of each test, hence assisting in the growth of the minimal residual disease industry. The increased prevalence of hematological malignancy and cancer and rising healthcare spending are expected to drive growth in the minimal residual disease sector throughout the forecast period.
The increased government and private sector investment in MRD research and increased consumer awareness of personalized therapy are propelling market expansion. On the other hand, the high expense of research and development operations is limiting market expansion.
Furthermore, the increase in R&D activities, the rise in tailored medications for treatment, and the spike in product development collaborations are all potential for market expansion. Additionally, rising demand for DNA testing due to developments in next-generation sequencing instruments and technologies, faster results, and cost-effectiveness compared to genotyping-based DNA microarray are driving market expansion.
List of Prominent Players in the Minimal Residual Disease Market:
• F. Hoffmann-La Roche Ag
• Laboratory Corporation Of America Holdings
• Guardant Health, Inc.
• Sysmex Corporation
• NEOGENOMICS Laboratories
• MOLECULARMD (A Subsidiary Of Icon Plc)
• Adaptive Biotechnologies
• ARCHERDX (Invitae Corporation)
• Bio-Rad Laboratories, Inc.
• Natera, Inc.
• OPKO Health, Inc.
• GENETRON Health
• Quest Diagnostics, Inc.
• ASURAGEN, Inc.
• INVIVOSCRIBE, Inc.
• Arup Laboratories Inc.
• Mission Bio, Inc.
• CERGENTIS B.V.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics:
Drivers-
The rising number of cancer patients and increased R&D spending are driving the expansion of the minimal residual disease market. Furthermore, the market is growing because of the increased implementation of next-generation sequencing (NGS) technology. Furthermore, technical developments in diagnostics and therapeutics due to increased R&D expenditure are boosting market expansion.
Besides, favourable government and private-sector initiatives for developing and adopting NGS technologies, technological advancements in cloud computing and the availability of a technologically advanced healthcare research framework are all stimulating market growth. In addition, the better regulatory and reimbursement landscape for NGS-based diagnostic tests and expanded genome mapping activities will drive market expansion throughout the projection period.
Challenges:
The high expense of research and development operations is limiting market expansion. The healthcare, industrial, technology, and pharmaceutical industries often incur the highest R&D costs.
Furthermore, despite significant progress toward expanding next-generation sequencing applications from research to the clinic, next-generation sequencing still presents massive challenges in quality control management, processing, data storage, and interpretation, slowing the translation from benchtop to bedside. This aspect is also impeding market expansion.
Regional Trends:
The North American minimal residual disease market is estimated to register a major share in the market during the forecast period. Because of rising healthcare costs in the United States, North America dominates the minimal residual disease industry.
Furthermore, the rise in drug discovery platforms that need NGS technology and the increased emphasis of companies on creating treatments and diagnostics for detecting minimum residual disease are propelling market expansion in this region. Besides, Asia Pacific had a substantial share in the minimal residual disease market.
The growing number of hospitals in emerging regions such as Asia Pacific will provide considerable potential opportunities for the minimal residual disease industry.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1448
Recent Developments:
• In January 2025, NeoGenomics revealed that it has entered into a multi-year exclusive strategic commercial partnership with Adaptive Biotechnologies Corporation to develop minimal residual disease (MRD) monitoring solutions for patients treated for specific blood malignancies.
• In November 2023, Adaptive Biotechnologies declared a multi-year, international translational partnership with BeiGene to evaluate minimal residual disease (MRD) throughout the company’s therapeutic pathway for patients with lymphoid cancers utilizing clonoSEQ assay technology.
Segmentation of Minimal Residual Disease Market-
By Product
• Assay Kits & Reagents
• Instruments
By Technology
• Polymerase Chain Reaction
• Next-Generation Sequencing
• Flow Cytometry
• Other Technologies
By Application
• Hematological Malignancies
o Leukemia
Myeloid Leukemia
Lymphocytic Leukemia
Other Leukemias
o Lymphoma
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
• Solid Tumors
• Multiple Myeloma
• Other Applications
By End User
• Hospitals & Specialty Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
Other End Users
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/global-minimal-residual-disease-market/1448
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
Insight Ace Analytics
Diana D’souza
+1 551 226 6109
diana.dsouza@insightaceanalytics.com
Source: EmailWire.Com
Source link
